logo-loader
viewA-Cap Resources Ltd

A-Cap Resources completes first leg of $5.8 million capital raising

project_map_358x266_53571aca32861.jpg

A-Cap Resources (ASX: ACB) has raised $1.32 million through a placement to institutional investors based in the United Kingdom as part of a broader $5.8 million capital raising.

Funds from the placement will enable critical path drilling, process design and environmental work at its Letlhakane Uranium Project in Botswana to commence immediately.

Letlhakane ranks as one of the largest under-developed uranium deposits in the world with a resource of 308 million pounds of U3O8 along with separate strata that contain 107.3 million tonnes of thermal coal.

The remaining $4.48 million will be raised through a fully underwritten 1 for 3.5 non-renounceable, entitlement offer of 81,824,282 new shares priced at $0.055 per share.

Ansheng Investment Company Ltd, an entity which is controlled by Angang Shen, a director of the A-Cap, will underwrite this offer.

Funds will also be used to advance the Company’s coal projects following positive reports received from independent consultants on the development potential of these assets.

Letlhakane Uranium Project


Letlhakane is one of few global uranium projects capable of commencing production within the next three years.

In February of 2013 the company completed an internal Scoping Study that evaluated a shallow open pit mining operation of less than 75 metres in depth, and heap leach process route to produce 3 million pounds of uranium per year over a mine life that exceeds 25 years.

Power, road, rail and water infrastructure is readily available while the project’s soft near-surface ore requires just low-cost mining and heap leach acid processing.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: A-Cap Resources Ltd

Price: 0.01 AUD

ASX:ACB
Market: ASX
Market Cap: $8.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

41 minutes ago

2 min read